P-glycoprotein interaction with risperidone and 9-OH-risperidone studiedin vitro, in knock-out mice and in drug-drug interaction experiments
- 1 November 2005
- journal article
- research article
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 20 (7) , 493-500
Abstract
The drug transporter P‐glycoprotein (P‐gp) influences drug distribution across the blood‐brain barrier (BBB) by actively extruding drugs into the neural capillaries. Several psychotropic drugs, including nortriptyline (NT) and risperidone (Risp), are substrates of P‐gp. Here we compared the in vitro P‐gp interactions of Risp and its major metabolite, 9‐OH‐Risperidone (OH‐Risp), with their distribution over the BBB in P‐gp knock‐out mice and in rats where P‐gp was inhibited. Km and Vmax were determined by an in vitro ATPase assay, and Vmax/Km ratios of 2.7 and 0.5 were recorded for Risp and OH‐Risp, respectively, suggesting that Risp is a better substrate for P‐gp than OH‐Risp. In Mdr1a (−/−) knock‐out mice, the brain‐serum ratios of both Risp and OH‐Risp were more than ten times those of control mice (14 and 11, respectively). When P‐gp was inhibited with cyclosporine A (CsA) in Wistar rats, the effect was an order of magnitude less than that observed for the knock‐out mice experiments (1–1.5 times the controls), and co‐administration of NT had no effect. In conclusion, both Risp and OH‐Risp interact with P‐gp in vitro, and P‐gp has a profound effect on Risp and OH‐Risp distribution over the BBB, as is evident from the knock‐out mice experiments. Drug–drug interaction effects in relation to P‐gp, however, appear to be more limited. Copyright © 2005 John Wiley & Sons, Ltd.Keywords
This publication has 32 references indexed in Scilit:
- Influence of P-glycoprotein inhibition on the distribution of the tricyclic antidepressant nortriptyline over the blood-brain barrierHuman Psychopharmacology: Clinical and Experimental, 2005
- THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODELDrug Metabolism and Disposition, 2005
- How significant is the role of P-glycoprotein in drug absorption and brain uptake?Drugs of Today, 2004
- A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depressionThe Pharmacogenomics Journal, 2002
- Drugs as P-glycoprotein substrates, inhibitors, and inducersDrug Metabolism Reviews, 2002
- Penetration of Amitriptyline, but Not of Fluoxetine, into Brain is Enhanced in Mice with Blood-Brain Barrier Deficiency Due to Mdr1a P-Glycoprotein Gene DisruptionNeuropsychopharmacology, 2000
- P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.Journal of Clinical Investigation, 1996
- Co-operative, competitive and non-competitive interactions between modulators of P-glycoproteinBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1996
- Comparisons of P‐glycoprotein expression in isolated rat brain microvessels and in primary cultures of endothelial cells derived from microvasculature of rat brain, epididymal fat pad and from aortaFEBS Letters, 1995
- Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugsCell, 1994